Pennington, NJ, United States of America

Paul E Morin

This inventor holds 22 USPTO granted patents and 6 published patent applications and 4 EPO patents, primarily in Biologics Development. Top assignees: Bristol-Myers Squibb Compnay, Other. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paul E Morin. Retrieved from https://idiyas.com/inventor/paul-e-morin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 6)

% Patents Active = 100.0

EPO Patents = 4 (Patent Applications = 11)

Average Co-Inventor Count = 7.8

ph-index = 9

Forward Citations = 208(Granted Patents)

Company Filing History:

21 out of 3,745

Bristol-Myers Squibb Compnay

patents

1 out of 834,601

Other

patents

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

FGF-21 Polypeptides

Modified Relaxin

PD-L1 Binding

Imaging Techniques

Fibrosis Treatment

Cardiovascular Disease

Biologics

Pharmacokinetic Enhancers

Prodrugs

Serum Albumin Binding

Kidney Failure

Protein Refolding

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12247058 - Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof (2025-03-11),

2. 12194110 - PD-L1 binding polypeptides for imaging (2025-01-14),

3. 12097242 - Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides (2024-09-24),

4. 12097241 - Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides (2024-09-24),

5. 11623965 - Prodruggable antibodies, prodrugs thereof, and methods of use and making (2023-04-11),

6. 11623013 - Methods and compositions for deuterated biologics (2023-04-11),

7. 11364281 - Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof (2022-06-21),

8. 11344639 - PET imaging with PD-L1 binding polypeptides (2022-05-31),

9. 11248031 - Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides (2022-02-15),

10. 11185570 - Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides (2021-11-30),

11. 11173219 - PD-L1 binding polypeptides for imaging (2021-11-16),

12. 10934572 - Serum albumin binding molecules (2021-03-02),

13. 10406251 - PD-L1 binding polypeptides for imaging (2019-09-10),

14. 10377806 - Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof (2019-08-13),

15. 10266578 - Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof (2019-04-23),

Title: Innovations and Contributions of Paul E. Morin

Introduction

Paul E. Morin, based in Pennington, NJ, is a prominent inventor with a remarkable portfolio of 22 patents. His contributions have significantly advanced the fields of biotechnology and therapeutics, particularly in treating diseases associated with fibrosis.

Latest Patents

Among his latest patents are two critical innovations:

1. Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereof. This patent presents nucleic acids that encode modified FGF-21 polypeptides, which can express therapeutic proteins essential in treating various fibrosis-related diseases.

2. PD-L1 binding polypeptides for imaging, which includes novel Fn3 domains specifically binding to PD-L1, facilitating the development of imaging agents for diagnostic purposes.

Career Highlights

Paul has worked with several esteemed organizations throughout his career, including Bristol-Myers Squibb Company, where he applied his expertise in drug development and innovative solutions in biomedicine.

Collaborations

Working alongside notable colleagues such as Dasa Lipovsek and Ray Camphausen, Paul E. Morin has fostered collaborations that have enriched the research landscape. These partnerships have played a crucial role in the success of his patent portfolio and the implementation of his groundbreaking ideas.

Conclusion

Paul E. Morin's extensive research and innovative patents exemplify his commitment to advancing medical science. His work continues to pave the way for new therapeutic solutions, showcasing the impactful role of inventors in transforming healthcare.

Profile summary based on public USPTO records.